<DOC>
	<DOC>NCT01670136</DOC>
	<brief_summary>The purpose of this study is to learn more about the safety and dosing of sildenafil in infants.</brief_summary>
	<brief_title>Pharmacokinetics of Sildenafil in Premature Infants</brief_title>
	<detailed_description>Pharmacokinetics and safety of sildenafil will be studied in preterm infants who are receiving sildenafil per standard of care or 1 dose prescribed for the study.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Cohort 1: Gestational age 28 weeks or less receiving sildenafil as standard of care &lt; 365 postnatal days Cohort 2: Gestational age 28 weeks or less 728 postnatal days of age Mechanical ventilation or nasal continuous positive airway pressure (NCPAP) or highflow nasal cannula Intravenous line in place Cohort 1: Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study Cohort 2: Previous exposure to sildenafil within 7 days prior to enrollment Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study History of allergic reactions to sildenafil AST &gt; ULN or ALT &gt; 3x ULN Currently on a vasopressor for hypotension Known sickle cell disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>364 Days</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sildenafil</keyword>
	<keyword>preterm infants</keyword>
	<keyword>persistent pulmonary hypertension of the newborn</keyword>
</DOC>